Stock BCAB BIOATLA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages BioAtla, Inc.

Equities

BCAB

US09077B1044

Real-time Estimate Cboe BZX
Other stock markets
 10:54:44 2024-06-10 am EDT 		5-day change 1st Jan Change
1.445 USD -4.93% Intraday chart for BioAtla, Inc. -10.69% -42.28%
May. 23 BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology Annual Meeting CI
May. 15 Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioAtla, Inc. Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology Annual Meeting
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
BioAtla, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Sector Update: Health Care Stocks Advance in Afternoon Trading
BioAtla Rallies After CEO Buys 50,000 Shares
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types
Sector Update: Health Care Stocks Slipping Tuesday Afternoon
BioAtla Says Clinical Benefits, Safety Profile Support Further Evaluation of Potential Lung Cancer Therapy
BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
Top Premarket Decliners
BioAtla, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Top Premarket Decliners
Viatris Projects Lower 2023 Revenue Despite Swinging to Fourth-Quarter Profit
BioAtla President Scott Smith to Leave; Appointed as CEO at Viatris
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCAB Stock
  4. News BioAtla, Inc.
  5. Other languages